文献速递抗栓抗凝管理药物不良反应与药物警戒

直接口服抗凝药在肝素诱导性血小板减少症管理中的潜在作用

Potential Role of Direct Oral Anticoagulants in the Management of Heparin-induced Thrombocytopenia.
PubMed 文献 · Pharmacotherapy · 2019-07-18

DOAC在98%(n=102)的病例中预防了新发和复发性血栓形成,出血并发症发生率为3%(n=3)。尽管现有文献有限,但提示DOACs在HIT中具有潜在作用,已获2018年美国血液学会指南有条件推荐。

要点

  • DOACs在104例HIT患者中预防新发和复发性血栓形成达98%(n=102)。
  • 出血并发症发生率为3%(n=3)。
  • 2018年美国血液学会指南对DOACs用于HIT给予有条件推荐。

核心结论

  • 现有文献虽有限,但提示DOACs(利伐沙班、阿哌沙班、达比加群)在HIT管理中具有潜在作用。
  • DOACs已被纳入2018年美国血液学会指南,获得有条件推荐。

研究设计与样本

  • 叙述性综述,检索PubMed、Google Scholar和MEDLINE数据库2012年1月1日至2018年6月31日的同行评议文献。

主要发现

  • DOACs在98%(n=102)的病例中预防了新发和复发性血栓形成。
  • 出血并发症发生率为3%(n=3)。

关键数值与推荐

  • 2018年美国血液学会指南对DOACs用于HIT给予有条件推荐。

临床怎么用

  • DOACs可能克服传统治疗需肠外给药和常规实验室监测的局限性。

局限性

  • 当前文献仍有限,证据主要来自回顾性研究和病例报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heparin-induced thrombocytopenia (HIT) is a rare, potentially life-threatening condition secondary to unfractionated heparin or low molecular weight heparin exposure. This immune-mediated drug reaction manifests as thrombocytopenia with a paradoxical hypercoagulable state that can result in life-threatening thrombosis. It is imperative to ensure cessation of heparin-based products as soon as HIT is identified. Traditional treatment options include argatroban, bivalirudin, fondaparinux, and danaparoid with a transition to warfarin upon platelet recovery. These anticoagulants are notwithstanding limitations including parenteral administration and routine laboratory monitoring leading to prolonged hospitalizations, emphasizing the need for new therapies. Direct oral anticoagulants (DOACs) have been increasingly investigated for the management of HIT and may overcome the aforementioned challenges of current therapies. The objective of this narrative review is to summarize the current HIT guidelines, discuss limitations to contemporary treatment options, provide insight into the emerging evidence for the DOACs rivaroxaban, apixaban, and dabigatran, and conclude with a clinical summary for their use in this setting. The PubMed, Google Scholar, and MEDLINE databases were searched for peer-reviewed literature from January 1, 2012, to June 31, 2018. Twenty-seven articles met inclusion criteria for review: 1 prospective trial, 5 retrospective cohort studies, and 21 case reports totaling 104 patients treated with a DOAC for HIT. The DOACs prevented new and recurrent thrombosis in 98% (n=102) of cases, and bleeding complications occurred in 3% (n=3). While current literature remains limited, it is suggestive of a potential role of DOACs for HIT, which has led to their integration into the 2018 American Society Hematology Guidelines with a conditional recommendation.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Barlow A, Barlow B, Reinaker T, et al. Potential Role of Direct Oral Anticoagulants in the Management of Heparin-induced Thrombocytopenia. Pharmacotherapy. 2019. PMID: 31233222. doi:10.1002/phar.2298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。